IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN. - ppt download
V_Hematology_Forum_Prof_Lowenberg
A Randomized Investigation of High-Dose Versus Standard-Dose Cytosine Arabinoside With Daunorubicin in Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study - ScienceDirect
The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia | Nature Communications
Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia Lei M, Liu L, Wang Z, Wu
PDF) Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells | Larry Matherly - Academia.edu
3942-Consolidation HiDAC (cytarabine) 1,2,3 | eviQ
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia | Haematologica
HDAC - high-dose ara-C
The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaem
Cytarabine (Cytosine β-D-arabinofuranoside) | DNA Synthesis Inhibitor | MedChemExpress
Cancers | Free Full-Text | HDAC Inhibitors in Acute Myeloid Leukemia | HTML
A new pattern of cytosineâ•'arabinosideâ•'induced lung toxicity
Cytarabine - Wikipedia
Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis
A: RFS and (B) OS of 130 patients given ARA-C at standard dose (SDAC,... | Download Scientific Diagram
Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy - ScienceDirect
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression - Journal of Biological Chemistry
Histone Deacetylase Inhibitors in Multiple Myeloma | SpringerLink
A DNA/HDAC dual‐targeting drug CY190602 with significantly enhanced anticancer potency | EMBO Molecular Medicine
Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response | Leukemia
IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN. - ppt download
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine
